MARKET DEFINITION

monkeypox is a viral zoonotic disease (a virus that spreads from animals to people) that is less severe than smallpox. Monkeypox has symptoms that are comparable to those of smallpox. Monkeypox has replaced smallpox as the most significant orthopoxvirus for public health since smallpox was eradicated in 1980 and smallpox vaccinations were subsequently discontinued. Primarily affecting central and west Africa, monkeypox has been spreading into cities and is frequently seen close to tropical rainforests. Numerous rodent species and non-human primates serve as hosts for animals.

MARKET DYNAMICS

The fear due to the COVID-19 pandemic will be the major driver for the treatment of the Monkeypox virus. The increasing number of deaths due to Monkeypox is pushing scientists to come up with drugs and companies to make it in mass numbers. Most of the disease load is coming from the African countries, which are demanding medicines. The virus is spreading fast in less developed regions due to unhygienic and non-protective sexual practices. Also due to the lower immunity in the regions due to high poverty and low nutrition levels in people.

REPORT SCOPE 

The report titled “Global Monkeypox Market – Size, Share, Growth, Opportunities, and Competitive Analysis, 2022 – 2028” offers strategic visions into the global Monkeypox market along with the market size (Value in “US$ Mn”) for the historical period 2017 to 2021 and estimates for the forecast period 2022 to 2028. The RI report is an in-depth study of the global Monkeypox market with a strong focus on key market trends, vital player strategies, and market forecasts. The study also covers key market dynamics, including drivers, restraints, opportunities, challenges, and existing and upcoming pathways that help CXOs make critical business decisions effectively. The global Monkeypox Market is predicted to grow at a significant CAGR over the forecast period from 2022 to 2028.

GEOGRAPHICAL OVERVIEW 

The research report includes a detailed overview of the industry comprising quantitative and qualitative information. It gives a broad overview of the worldwide market forecasts for major segments. It also includes market size and forecast projections for five key regions: North America, Europe, Asia-Pacific (APAC), South America, and the Middle East & Africa (MEA), for the years 2017 to 2028. The market is further divided by categories and countries within each province. The research scrutinizes and forecasts over 20 nations worldwide, as well as the present trend and possibilities in these regions.

 

MARKET SEGMENTATION 

The Global Monkeypox Market is segmented based on Vector, Potential Medication, Mode of Transmission, End-user, Distribution Channel, and region. Based on Vector, the market has been segmented into Rope squirrels, Tree squirrels, Gambian pouched rats, Dormice, Non-human primates, and Others, whereas based on Potential Medication, the market comprises Cidofovir, Brincidofovir, Tecovirimat, and Vaccinia Immune Globulin. Based on the Mode of Transmission, the market has been segmented into Blood, Bodily fluids, Cutaneous, and Mucosal lesions, whereas, the End-user segmentation includes Clinics, Hospitals, and Others. Based on the Distribution Channel, the market is segmented as Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others.

COMPETITION LANDSCAPE 

The RI research report discusses noteworthy developments in the industry as well as organic and inorganic growth strategies being adopted by the Monkeypox market players. The report covers industry activities, including new product launches, mergers & acquisitions, business partnerships, and various expansion initiatives being undertaken by the active players in the market. These developments pave the path for various market participants to strengthen their positioning as well as expand their consumer base. The positive market outlook for the global Monkeypox market is anticipated to present lucrative growth opportunities to the market players. The report also offers detailed profiles of major players in the global Monkeypox market, emphasizing the strategic initiatives, financial information, SWOT analysis, and key development in the Monkeypox industry in the past three years.

Key players in the Global Monkeypox Market have adopted various organic as well as inorganic growth strategies to strengthen their market positioning. Prominent players in the market include:

·         Bavarian Nordic

·         SIGA Technologies

·         Chimerix

·         Tonix Pharmaceuticals Holding Corp

·         Emergent BioSolutions

·         Abbott

·         Emcure Pharma UK Ltd

·         Gilead Sciences

·         Moderna

·         Grifols

COVID-19 IMPACT ANALYSIS ON GLOBAL MONKEYPOX MARKET 

The COVID-19 pandemic is still a very personal, individual experience that is also a once-in-a-lifetime worldwide phenomenon with far-reaching consequences. The epidemic has wreaked havoc on people's lives in all nations and communities and also had a negative impact on global economic development in 2020, unlike anything seen in almost a century. The pandemic severely impacted key economies such as India, Brazil, the U.S., France, Russia, the UK, Italy, Turkey, and Argentina. According to estimates, the virus slowed global economic growth by -3.4 percent to -7.6 percent in 2020, with a rebound of 4.2 percent to 5.6 percent expected in 2021. In 2020, global commerce was expected to decline by 5.3 percent, but it is expected to rise by 8.0 percent in 2021.

In contrast to the global economic downturn in the first half of 2020, the economy began to showcase symptoms of a two-track recovery post the second quarter of 2020, with a fledgling rebound in developed nations, however, slower growth in emerging economies. The outbreak of the Covid-19 pandemic has not only resulted in halted production activity but has also disrupted the global supply chain. The research goes on to evaluate the current and future implications of the COVID-19 pandemic both on the target as well as broader market, thereby, providing accurate and trustworthy forecasts.

 

Report Attribute/Metric	Details
Market Size	In USD Million
CAGR	In % (2022-2028)
Base Year	2021
Forecast Period	2022 – 2028
Historical Data	2017 to 2021
Forecast Unit	Value (US$ Mn)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors and Trends
Geographies Covered	North America, Europe, Asia-Pacific, South America, and Middle East & Africa
Key Players Analyzed	Bavarian Nordic, SIGA Technologies, Chimerix, Tonix Pharmaceuticals Holding Corp, Emergent BioSolutions, Abbott, Emcure Pharma UK Ltd, Gilead Sciences, Moderna, and Grifols
Customization & Pricing	Available on Request (10% Customization is Free)

 

RESEARCH PROGRAM DESIGN

KEY QUESTIONS ANSWERED 

1.    What is the current size of the global Monkeypox market?

2.    What will be the growth rate of the market over the forecast period?

3.    Who are the key manufacturers/vendors in the Monkeypox market space?

4.    What are the major market opportunities and market risks faced by the market?

5.    What is the impact of COVID-19 on the market?

6.    What are the revenue, sales, and price analysis of the top manufacturers in this market?

7.    What are the key outcomes of Porter's five forces model?

8.    Who are the distributors, traders, and vendors in the industry?

REASONS FOR BUYING THIS REPORT:

·         The report offers comprehensive data on the Monkeypox market elaborating on the current state and future growth prospects both globally and regionally

·         It offers a six-year market forecast trend evaluating the impact of drivers and restraints and supporting factors for growth

·         The report offers deep-dive insights into each market segment and critical factors responsible for its growth

·         The report presents precise picture of the dynamic competitive landscape which helps our client advance their market position

·         The comprehensive analysis of the market along with the inclusion of analyst recommendations ensures that our clients make informed business decisions

·         Cross-segment country-level analysis included in the report which provides granular analysis of more than 20+ countries covered in the report scope

·         The study includes detailed profiles of major manufacturers to help our readers gain holistic overview of the market competitors and consequently align their business strategies

 

Chapter 1.  Executive Summary

1.1.   Market Outlook

1.2.   Market Segment Outlook

1.3.   Geography Outlook

1.4.   Absolute $ Opportunity

Chapter 2.  Research Methodology

2.1.   Research Approach

2.2.   Scope, Definition, and Assumptions

2.3.   Data Sources

2.3.1. Secondary Sources

2.3.1.1.         Preliminary Data Mining

2.3.2. Primary Sources

2.3.2.1.         Statistical Mode of Transmission

2.3.2.2.         Data Triangulation

2.3.2.3.         Research Objective

Chapter 3.  Market Outlook

3.1.   Introduction

3.2.   Key Trends

3.2.1. Vector Trends

3.2.2. Potential Medication Trends

3.2.3. Mode of Transmission Trends

3.2.4. End-user Trends

3.2.5. Distribution Channel Trends

3.3.   Market Dynamics

3.3.1. Market Drivers

3.3.1.1.         Impact Analysis of Market Drivers

3.3.2. Market Restraints

3.3.2.1.         Impact Analysis of Market Restraints

3.3.3. Market Opportunities

3.3.3.1.         Impact Analysis of Market Opportunities

3.3.4. Market Challenges

3.3.4.1.         Impact Analysis of Market Challenges

3.4.   Porter’s Five Forces’ Analysis

3.4.1. Bargaining Power of Suppliers

3.4.2. Bargaining Power of Buyers

3.4.3. Threat of New Entrant

3.4.4. Threat of Substitutes

3.4.5. Competitive Rivalry

3.5.   Value Chain Analysis: Global Monkeypox Market

3.6.   COVID-19 Impact Assessment in Monkeypox Market

3.6.1. Impact Assessment on Global Monkeypox Market

3.6.2. Market Trends and Opportunities in the Covid-19 Landscape

Chapter 4.  Global Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

4.1.   Global Monkeypox Market Share, By Vector, 2017 - 2028 (USD Million)

4.1.1. Rope squirrels

4.1.2. Tree squirrels

4.1.3. Gambian pouched rats

4.1.4. Dormice

4.1.5. Non-human primates

4.1.6. Others

Chapter 5.  Global Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

5.1.   Global Monkeypox Market Share, By Potential Medication, 2017 - 2028 (USD Million)

5.1.1. Cidofovir

5.1.2. Brincidofovir

5.1.3. Tecovirimat

5.1.4. Vaccinia Immune Globulin

Chapter 6.  Global Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

6.1.   Global Monkeypox Market Share, By Mode of Transmission, 2017 - 2028 (USD Million)

6.1.1. Blood

6.1.2. Bodily fluids

6.1.3. Cutaneous

6.1.4. Mucosal lesions

Chapter 7.  Global Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

7.1.   Global Monkeypox Market Share, By End-user, 2017 - 2028 (USD Million)

7.1.1. Clinics

7.1.2. Hospitals

7.1.3. Others

Chapter 8.  Global Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

8.1.   Global Monkeypox Market Share, By Distribution Channel, 2017 - 2028 (USD Million)

8.1.1. Direct Tender

8.1.2. Hospital Pharmacy

8.1.3. Retail Pharmacy

8.1.4. Online Pharmacy

8.1.5. Others

Chapter 9.  Global Monkeypox Market Overview, By Geography, 2017 - 2028 (USD Million)

9.1.   Global Monkeypox Market Share, By Geography, 2017 - 2028 (USD Million)

9.1.1. Market Potential Medication and Projections, by Countries, 2017 - 2028 (USD Million)

9.1.2. Market Share and CAGR Comparison, by Countries, 2021 (%)

Chapter 10.      North America Monkeypox Market Overview, By Countries, 2017 - 2028 (USD Million)

10.1.  North America Monkeypox Market Overview, 2017 - 2028 (USD Million)

10.1.1.   Market Potential Medication and projections, 2017 - 2028 (USD Million)

10.1.2.   North America Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

10.1.3.   North America Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

10.1.4.   North America Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

10.1.5.   North America Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

10.1.6.   North America Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

10.2.  North America Monkeypox Market Overview, By Countries, 2017 - 2028 (USD Million)

10.2.1.   U.S. Monkeypox Market Overview, 2017 - 2028 (USD Million)

10.2.1.1.       U.S. Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

10.2.1.2.       U.S. Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

10.2.1.3.       U.S. Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

10.2.1.4.       U.S. Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

10.2.1.5.       U.S. Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

10.2.2.   Canada Monkeypox Market Overview, 2017 - 2028 (USD Million)

10.2.2.1.       Canada Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

10.2.2.2.       Canada Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

10.2.2.3.       Canada Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

10.2.2.4.       Canada Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

10.2.2.5.       Canada Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

10.2.3.   Mexico Monkeypox Market Overview, 2017 - 2028 (USD Million)

10.2.3.1.       Mexico Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

10.2.3.2.       Mexico Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

10.2.3.3.       Mexico Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

10.2.3.4.       Mexico Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

10.2.3.5.       Mexico Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

Chapter 11.      Europe Monkeypox Market Overview, By Countries, 2017 - 2028 (USD Million)

11.1.  Europe Monkeypox Market Overview, 2017 - 2028 (USD Million)

11.1.1.   Market Potential Medication and projections, 2017 - 2028 (USD Million)

11.1.2.   Europe Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

11.1.3.   Europe Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

11.1.4.   Europe Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

11.1.5.   Europe Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

11.1.6.   Europe Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

11.2.  Europe Monkeypox Market Overview, By Countries, 2017 - 2028 (USD Million)

11.2.1.   Germany Monkeypox Market Overview, 2017 - 2028 (USD Million)

11.2.1.1.       Germany Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

11.2.1.2.       Germany Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

11.2.1.3.       Germany Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

11.2.1.4.       Germany Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

11.2.1.5.       Germany Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

11.2.2.   France Monkeypox Market Overview, 2017 - 2028 (USD Million)

11.2.2.1.       France Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

11.2.2.2.       France Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

11.2.2.3.       France Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

11.2.2.4.       France Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

11.2.2.5.       France Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

11.2.3.   UK Monkeypox Market Overview, 2017 - 2028 (USD Million)

11.2.3.1.       UK Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

11.2.3.2.       UK Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

11.2.3.3.       UK Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

11.2.3.4.       UK Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

11.2.3.5.       UK Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

11.2.4.   Italy Monkeypox Market Overview, 2017 - 2028 (USD Million)

11.2.4.1.       Italy Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

11.2.4.2.       Italy Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

11.2.4.3.       Italy Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

11.2.4.4.       Italy Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

11.2.4.5.       Italy Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

11.2.5.   Spain Monkeypox Market Overview, 2017 - 2028 (USD Million)

11.2.5.1.       Spain Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

11.2.5.2.       Spain Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

11.2.5.3.       Spain Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

11.2.5.4.       Spain Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

11.2.5.5.       Spain Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

11.2.6.   NORDIC Monkeypox Market Overview, 2017 - 2028 (USD Million)

11.2.6.1.       NORDIC Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

11.2.6.2.       NORDIC Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

11.2.6.3.       NORDIC Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

11.2.6.4.       NORDIC Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

11.2.6.5.       NORDIC Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

11.2.7.   Russia and CIS Monkeypox Market Overview, 2017 - 2028 (USD Million)

11.2.7.1.       Russia and CIS Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

11.2.7.2.       Russia and CIS Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

11.2.7.3.       Russia and CIS Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

11.2.7.4.       Russia and CIS Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

11.2.7.5.       Russia and CIS Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

11.2.8.   Rest of Europe Monkeypox Market Overview, 2017 - 2028 (USD Million)

11.2.8.1.       Rest of Europe Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

11.2.8.2.       Rest of Europe Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

11.2.8.3.       Rest of Europe Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

11.2.8.4.       Rest of Europe Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

11.2.8.5.       Rest of Europe Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

Chapter 12.      Asia Pacific Monkeypox Market Overview, By Countries, 2017 - 2028 (USD Million)

12.1.  Asia Pacific Monkeypox Market Overview, 2017 - 2028 (USD Million)

12.1.1.   Market Potential Medication and projections, 2017 - 2028 (USD Million)

12.1.2.   Asia Pacific Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

12.1.3.   Asia Pacific Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

12.1.4.   Asia Pacific Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

12.1.5.   Asia Pacific Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

12.1.6.   Asia Pacific Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

12.2.  Asia Pacific Monkeypox Market Overview, By Countries, 2017 - 2028 (USD Million)

12.2.1.   India Monkeypox Market Overview, 2017 - 2028 (USD Million)

12.2.1.1.       India Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

12.2.1.2.       India Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

12.2.1.3.       India Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

12.2.1.4.       India Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

12.2.1.5.       India Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

12.2.2.   China Monkeypox Market Overview, 2017 - 2028 (USD Million)

12.2.2.1.       China Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

12.2.2.2.       China Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

12.2.2.3.       China Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

12.2.2.4.       China Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

12.2.2.5.       China Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

12.2.3.   Japan Monkeypox Market Overview, 2017 - 2028 (USD Million)

12.2.3.1.       Japan Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

12.2.3.2.       Japan Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

12.2.3.3.       Japan Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

12.2.3.4.       Japan Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

12.2.3.5.       Japan Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

12.2.4.   ASEAN Monkeypox Market Overview, 2017 - 2028 (USD Million)

12.2.4.1.       ASEAN Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

12.2.4.2.       ASEAN Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

12.2.4.3.       ASEAN Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

12.2.4.4.       ASEAN Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

12.2.4.5.       ASEAN Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

12.2.5.   South Korea Monkeypox Market Overview, 2017 - 2028 (USD Million)

12.2.5.1.       South Korea Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

12.2.5.2.       South Korea Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

12.2.5.3.       South Korea Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

12.2.5.4.       South Korea Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

12.2.5.5.       South Korea Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

12.2.6.   Australia Monkeypox Market Overview, 2017 - 2028 (USD Million)

12.2.6.1.       Australia Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

12.2.6.2.       Australia Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

12.2.6.3.       Australia Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

12.2.6.4.       Australia Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

12.2.6.5.       Australia Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

12.2.7.   Rest of Asia Pacific Monkeypox Market Overview, 2017 - 2028 (USD Million)

12.2.7.1.       Rest of Asia Pacific Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

12.2.7.2.       Rest of Asia Pacific Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

12.2.7.3.       Rest of Asia Pacific Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

12.2.7.4.       Rest of Asia Pacific Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

12.2.7.5.       Rest of Asia Pacific Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

Chapter 13.      South America Monkeypox Market Overview, By Countries, 2017 - 2028 (USD Million)

13.1.  South America Monkeypox Market Overview, 2017 - 2028 (USD Million)

13.1.1.   Market Potential Medication and projections, 2017 - 2028 (USD Million)

13.1.2.   South America Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

13.1.3.   South America Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

13.1.4.   South America Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

13.1.5.   South America Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

13.1.6.   South America Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

13.2.  South America Monkeypox Market Overview, By Countries, 2017 - 2028 (USD Million)

13.2.1.   Brazil Monkeypox Market Overview, 2017 - 2028 (USD Million)

13.2.1.1.       Brazil Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

13.2.1.2.       Brazil Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

13.2.1.3.       Brazil Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

13.2.1.4.       Brazil Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

13.2.1.5.       Brazil Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

13.2.2.   Argentina Monkeypox Market Overview, 2017 - 2028 (USD Million)

13.2.2.1.       Argentina Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

13.2.2.2.       Argentina Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

13.2.2.3.       Argentina Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

13.2.2.4.       Argentina Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

13.2.2.5.       Argentina Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

13.2.3.   Rest of South America Monkeypox Market Overview, 2017 - 2028 (USD Million)

13.2.3.1.       Rest of South America Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

13.2.3.2.       Rest of South America Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

13.2.3.3.       Rest of South America Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

13.2.3.4.       Rest of South America Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

13.2.3.5.       Rest of South America Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

Chapter 14.      Middle East & Africa Monkeypox Market Overview, By Countries, 2017 - 2028 (USD Million)

14.1.  Middle East & Africa Monkeypox Market Overview, 2017 - 2028 (USD Million)

14.1.1.   Market Potential Medication and projections, 2017 - 2028 (USD Million)

14.1.2.   Middle East & Africa Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

14.1.3.   Middle East & Africa Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

14.1.4.   Middle East & Africa Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

14.1.5.   Middle East & Africa Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

14.1.6.   Middle East & Africa Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

14.2.  Middle East & Africa Monkeypox Market Overview, By Countries, 2017 - 2028 (USD Million)

14.2.1.   GCC Monkeypox Market Overview, 2017 - 2028 (USD Million)

14.2.1.1.       GCC Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

14.2.1.2.       GCC Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

14.2.1.3.       GCC Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

14.2.1.4.       GCC Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

14.2.1.5.       GCC Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

14.2.2.   South Africa Monkeypox Market Overview, 2017 - 2028 (USD Million)

14.2.2.1.       South Africa Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

14.2.2.2.       South Africa Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

14.2.2.3.       South Africa Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

14.2.2.4.       South Africa Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

14.2.2.5.       South Africa Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

14.2.3.   Rest of Middle East & Africa Monkeypox Market Overview, 2017 - 2028 (USD Million)

14.2.3.1.       Rest of Middle East & Africa Monkeypox Market Overview, By Vector, 2017 - 2028 (USD Million)

14.2.3.2.       Rest of Middle East & Africa Monkeypox Market Overview, By Potential Medication, 2017 - 2028 (USD Million)

14.2.3.3.       Rest of Middle East & Africa Monkeypox Market Overview, By Mode of Transmission, 2017 - 2028 (USD Million)

14.2.3.4.       Rest of Middle East & Africa Monkeypox Market Overview, By End-user, 2017 - 2028 (USD Million)

14.2.3.5.       Rest of Middle East & Africa Monkeypox Market Overview, By Distribution Channel, 2017 - 2028 (USD Million)

Chapter 15.      Competitive Landscape

15.1.  Competitive Environment, 2021

15.2.  Strategic Framework

15.2.1.   Partnership/Collaborations/Agreement

15.2.2.   Expansion

15.2.3.   Mergers & Acquisitions

15.2.4.   New Product Development

Chapter 16.      Key Vendor Analysis

16.1.              Bavarian Nordic

16.1.1.       Business Overview

16.1.2.       Product Benchmarking

16.1.3.       Financial Data

16.1.4.       Strategic Overview

16.1.5.       Key Developments

16.1.6.       SWOT Analysis

16.2.              SIGA Technologies

16.2.1.       Business Overview

16.2.2.       Product Benchmarking

16.2.3.       Financial Data

16.2.4.       Strategic Overview

16.2.5.       Key Developments

16.2.6.       SWOT Analysis

16.3.              Chimerix

16.3.1.       Business Overview

16.3.2.       Product Benchmarking

16.3.3.       Financial Data

16.3.4.       Strategic Overview

16.3.5.       Key Developments

16.3.6.       SWOT Analysis

16.4.              Tonix Pharmaceuticals Holding Corp

16.4.1.       Business Overview

16.4.2.       Product Benchmarking

16.4.3.       Financial Data

16.4.4.       Strategic Overview

16.4.5.       Key Developments

16.4.6.       SWOT Analysis

16.5.              Emergent BioSolutions

16.5.1.       Business Overview

16.5.2.       Product Benchmarking

16.5.3.       Financial Data

16.5.4.       Strategic Overview

16.5.5.       Key Developments

16.5.6.       SWOT Analysis

16.6.              Abbott

16.6.1.       Business Overview

16.6.2.       Product Benchmarking

16.6.3.       Financial Data

16.6.4.       Strategic Overview

16.6.5.       Key Developments

16.6.6.       SWOT Analysis

16.7.              Emcure Pharma UK Ltd

16.7.1.       Business Overview

16.7.2.       Product Benchmarking

16.7.3.       Financial Data

16.7.4.       Strategic Overview

16.7.5.       Key Developments

16.7.6.       SWOT Analysis

16.8.              Gilead Sciences

16.8.1.       Business Overview

16.8.2.       Product Benchmarking

16.8.3.       Financial Data

16.8.4.       Strategic Overview

16.8.5.       Key Developments

16.8.6.       SWOT Analysis

16.9.              Moderna

16.9.1.       Business Overview

16.9.2.       Product Benchmarking

16.9.3.       Financial Data

16.9.4.       Strategic Overview

16.9.5.       Key Developments

16.9.6.       SWOT Analysis

16.10.            Grifols

16.10.1.    Business Overview

16.10.2.    Product Benchmarking

16.10.3.    Financial Data

16.10.4.    Strategic Overview

16.10.5.    Key Developments

16.10.6.    SWOT Analysis

Chapter 17.   Future Outlook of the Market